Using memantine to treat patients with cirrhosis and liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective study aims to evaluate the efficacy of memantine in patients with unresectable hepatocellular carcinoma (HCC) who are not suitable candidates for intensive systemic therapy. The study will assess primary and secondary efficacy endpoints, as well as monitor changes in patients' quality of life over time while undergoing treatment. Participants must have a confirmed diagnosis of HCC and a Child-Pugh cirrhosis score of B7 or greater. The study is conducted at a single site, the Inova Schar Cancer Institute in Virginia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 or older.
2. Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesion that is measurable by RECIST 1.1 criteria. A prior HCC lesion that was treated surgically or by radiation is allowed as long as it was at least 2 years or more from the current HCC diagnosis.
3. Patient's cancer must be deemed locally advanced and unresectable as per the consensus of the Inova Multidisciplinary Cancer Care Conference.
4. Patients must have a Child-Pugh cirrhosis score of B7 or greater and deemed not a candidate for aggressive systemic treatment.
5. Eastern Cooperative Oncology Group Performance Status of 0-2.
6. Patients must have adequate blood counts and organ function.
7. Memantine is harmful to the human fetus. For this reason, sexually active males with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study. Women of child bearing potential must have a negative serum pregnancy test result within 24 hours prior to initiation of study treatment. They must also agree to use agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study.
8. Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.
9. Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study.

Exclusion Criteria:

1. Patients with Child-Pugh A cirrhosis.
2. Female patients who are pregnant or breast-feeding.
3. Concomitant illness or history that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
4. Life-threatening intercurrent illness.
5. Anticipated poor compliance.
6. Subject is enrolled in a separate interventional clinical trial.
7. Active tuberculosis.
8. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
9. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
10. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry for at least 10 days prior to study entry.
11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.
12. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
13. Patients undergoing other anti-cancer treatment. Palliative radiation for symptom control will be allowed while on protocol.

Where it's running

• Inova Schar Cancer Institute
  Fairfax, Virginia, United States Recruiting
• Inova Health Care Service
  Falls Church, Virginia, United States Not yet recruiting

Study contacts

• Principal investigator: Arthur Winer, MD — Inova Health Care Service
• Study coordinator: Elahe Mollapour
• Email: elahe.mollapour@inova.org
• Phone: 571-472-0615

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abbreviated non-contrast MRI versus ultrasound for finding liver cancer in people with cirrhosis

  We will test whether shorter MRI scans without contrast find liver cancer more reliably than routine ultrasound in adults with cirrhosis or otherwise at high risk.

  Recruiting at 2 sites University of Oxford · Oxford, Oxon and 1 other locations · NCT06658782

• Early detection of liver cancer in patients with cirrhosis

  This study is testing new ways to find liver cancer early in people with cirrhosis by looking at blood, urine, and other health information over four years.

  Recruiting University of Oxford · Oxford, Oxfordshire · NCT05541601

• Treatment of advanced liver cancer with namodenoson in patients with severe cirrhosis

  This study is testing if a new drug called namodenoson can help people with advanced liver cancer and severe cirrhosis feel better and live longer compared to a placebo.

  Recruiting at 11 sites Phase 3 Can-Fite BioPharma · Dallas, Texas and 31 other locations · NCT05201404

• Fast-MRI to improve liver cancer surveillance in high-risk patients

  This trial will test whether adding a fast liver MRI to the routine six-month ultrasound finds early liver cancers sooner in adults with cirrhosis who have an annual HCC risk above 3%.

  Recruiting Assistance Publique - Hôpitaux de Paris · Bondy · NCT05095714

• Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis

  This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.

  Recruiting University Medical Center Ho Chi Minh City (UMC) · Ho Chi Minh City · NCT07918378

• EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis

  This trial tests whether using endoscopic ultrasound to guide coils plus glue works better than glue alone for stopping bleeding from gastric varices in adults with cirrhosis.

  Recruiting Medanta, The Medicity, India · Orlando, Florida and 1 other locations · NCT07855913

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.